Department of Immunology, Genetics and Pathology, Uppsala University and SciLifeLab, Uppsala, Sweden.
Mol Oncol. 2021 Jun;15(6):1715-1726. doi: 10.1002/1878-0261.12809. Epub 2020 Nov 17.
Cancer diagnostics based on the detection of protein biomarkers in blood has promising potential for early detection and continuous monitoring of disease. However, the currently available protein biomarkers and assay formats largely fail to live up to expectations, mainly due to insufficient diagnostic specificity. Here, we discuss what kinds of plasma proteins might prove useful as biomarkers of malignant processes in specific organs. We consider the need to search for biomarkers deep down in the lowest reaches of the proteome, below current detection levels. In this regard, we comment on the poor molecular detection sensitivity of current protein assays compared to nucleic acid detection reactions, and we discuss requirements for achieving detection of vanishingly small amounts of proteins, to ensure detection of early stages of malignant growth through liquid biopsy.
基于血液中蛋白质生物标志物检测的癌症诊断在疾病的早期发现和持续监测方面具有很大的潜力。然而,目前可用的蛋白质生物标志物和检测方法在很大程度上未能达到预期,主要是由于诊断特异性不足。在这里,我们讨论了哪些类型的血浆蛋白可能被证明对特定器官恶性过程有用的生物标志物。我们认为需要在蛋白质组的最底层,在当前检测水平以下寻找生物标志物。在这方面,我们对目前蛋白质检测方法与核酸检测反应相比分子检测灵敏度较差的情况进行了评论,并讨论了实现对极少量蛋白质进行检测的要求,以通过液体活检确保对恶性生长早期阶段的检测。